Drugs / FT024
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07665021 | Jun 2026 → Jun 2030 expected | osteopetrosis | Fondazione Telethon | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07665021 ↗ |
| Modality | Cell therapy | “Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA and expanded ex vivo.” NCT07665021 ↗ |
| Route | Intravenous | “The route of administration will be intravenous infusion.” NCT07665021 ↗ |
| Target | TCIRG1 | “Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA and expanded ex vivo.” NCT07665021 ↗ |